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【Abstract】Life-threatening in the short term and
leading to a high level of morbidity in the long term, venous
thromboembolism (VTE) is the most fearful complication
following lower limb arthroplasty. With advances in surgi-
cal procedure, anesthetic management and postoperative
convalescence have altered the risks of venous thromboem-
bolism after total joint arthroplasty in the lower extremity.
The pathogenesis of VTE is multifactorial and includes the
well-known Virchow’s triad of hypercoagulability, venous
stasis and endothelial damage. Therefore, it is appropriate
to use a multimodal approach to thromboprophylaxis. De-
spite extensive research, the ideal multimodal prophylaxis
against venous thrombolism has not been identified. So
this article reviews the recent developments in multimodal
prophylaxis for thromboembolism after total joint
arthroplasty.
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Venous thromboembolic disease (VTED) is a se-rious and frequent complication of orthopedicsurgery. Total joint arthroplasty in the lower
extremity is an operation with a strong propensity for
thromboembolic complications with potentially life-
threatening consequences. Elective total hip arthro-
plasty (THA) and total knee arthroplasty (TKA) carry a
high risk of postoperative venous thromboembolism
(VTE), a serious and potentially fatal condition when it
presents as deep vein thrombosis (DVT) and pulmo-
nary embolism (PE).1,2 American College of Chest Phy-
sicians (ACCP) and American Academy of Orthopaedic
Surgeons have concluded that multimodal prophylaxis
is the recommended safe and effective protection
against thrombotic events.3
Pathogenesis
The formation of thrombi is associated with Virchow’s
triad of venous stasis, endothelial injury and hyper-
coagulability.4
Stasis of blood may occur because of immobility,
age, obesity, or disease processes. Venous stasis is
particularly a problem in orthopedic surgery because of
tourniquet use in TKA and positioning of the extremity
in THA. The problem is compounded by stasis in the
lower extremity caused by obstruction of femoral venous
flow, either while the lower extremity is kept in an ex-
treme position to provide adequate exposure for femo-
ral preparation and hip component insertion or with the
leg folded upon itself to gain exposure of the proximal
tibia during knee replacement. 5,6 It has been shown in
vitro that obstruction of venous flow for just 10 minutes
is enough to stimulate thrombus formation in the pres-
ence of a thrombogenic stimuli. 7
Damage to the epithelial cell lining of blood vessel
is one of the extrinsic factors triggering the clotting
cascade. The damaged endothelium attempts to main-
tain vascular integrity by adhesion and aggregation of
platelets. As the clotting cascade continues, the final
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step is the formation of thrombin, which leads to the
conversion of fibrinogen to fibrin and the formation of a
fibrin clot.8 Kinking of the femoral or popliteal veins dur-
ing total hip and knee arthroplasty can produce endot-
helial injury, providing the nidus for the formation and
propagation of clots.
Hypercoagulability may be caused by various dis-
ease processes and medications. It has been proved
during the reaming of the femur and insertion of the
implant in THA that there are increased numbers of pro-
thrombin-F1.2, thrombin-antithrombin complexes and
fibrin peptide A,10 which leads to hyper-coagulability. A
relative hypercoagulable state can develop during the
procedure because blood loss can result in reduction
in antithrombin III and inhibition of the endogenous fi-
brinolytic system, which further promote thrombus propa-
gation during the total hip and knee arthroplasty. 2, 9,10
Epidemiology
In the1970s, the incidence of symptomatic PE after
THAs was reported to be as much as 8% in the ab-
sence of prophylaxis, with a fatality rate of 1%.11 The
American National Institutes of Health Consensus Con-
ference in 1986 further raised the general awareness of
the high risk of DVT and PE and stratified patient risks
by types of surgery.12 Based on data available at that
time, orthopaedic surgery of the lower extremity, in-
cluding TKA, THA, and hip fracture, were determined
to present the highest risk for VTED without
prophylaxis.
A number of risk factors for the development of DVT
have been identified, including recognized clinical risk
factors, controversial or weak risk factors, and genetic
risk factors. However, even without underlying risk
factors, patients who undergo total joint arthroplasty
are at high risk for the development of VTE.13, 14 More
recent studies have reported that without the use of
prophylaxis following THA, the prevalence of venographic
VTE might be as high as 93% and fatal PE may de-
velop in up to 2% of patients.3 From these data, we
could consider that the morbidity of VTE is very high
among the patients without prophylaxis after total joint
arthroplasty.
Since surgical practice and postoperative care have
substantially changed in the last 40 years as a result
of improved knowledge on pathophysiology, kinemat-
ics and material science, it is likely that the morbidity
of VTE after total joint arthroplasty has decreased. In a
meta-analysis of 130 000 patients who had THA, Murray
et al15 found that the overall mortality was 0.30% (10
of  3 355) among patients who did not received
prophylaxis, 0.40% (40 of 10 105) among those who
received heparin, 0.29% (11 of 3 763) among those who
received warfarin, 0.15% (4 of 2 649) among those who
received aspirin, and 0.50% (13 of 2 618) among those
who received dextran, respectively. Recently the reported
incidence of fatal PE has been much lower (0-0.2%).16 In
the UK, the 30-day incidence of fatal PE following TKA
and THA was 0.07%; the overall death rate was 0.31%
(13 of 4 253) and the rate of fatal PE was 0.07% (3 of
4 253).17 This is probably due to a combination of im-
proved surgical technique of spinal anesthesia18 and
early mobilization, rather than any prophylaxis for
thromboembolism.
Multimodal prophylaxis for VTE after total joint
arthroplasty
Nowadays, measures to prevent VTE after total joint
replacement are almost universally used and probably
the most widely disseminated guidelines are those pro-
posed by ACCP.3 But some within the orthopaedic com-
munity have challenged these recommendations as
being not entirely applicable to the patients undergoing
THA and TKA.19 The two guides both suggest multimodal
prophylaxis for thromboembolism after total joint
arthroplasty, especially with high risk of bleeding.
Anesthesia: regional anesthesia    Spinal anes-
thesia can reduce blood loss and transfusion require-
ment and increase lower extremity blood flow in com-
parison to general anesthesia. A number of studies20, 21
have demonstrated a reduced rate of DVT after THA
with spinal or epidural anesthesia. It has been postu-
lated that the decreased rate of thrombosis in these
patients may be secondary to improved blood flow in
the lower extremities and a decrease in blood loss and
transfusion requirements. Randomized trials have shown
that regional anesthesia (spinal or epidural) reduces
the risk of DVT (proximal and distal) and PE following
hip surgery by 40%-50%.22
The technique of hypotensive epidural anesthesia
(HEA) increases lower extremity blood flow more than
epidural anesthesia alone.23 Enhanced blood flow in the
immediate postoperative period with HEA may be im-
Chinese Journal of Traumatology 2010; 13(6):362-369. 364 .
portant as a bridging technique before pneumatic com-
pression devices are instituted. In a study,24 the au-
thors compared HEA and hypotensive total intravenous
anesthesia (HTIVA) with propofol and remifentanil on
blood loss during primary total hip replacement. The
result showed that intraoperative blood loss, percent-
age of patients receiving blood substitution, and total
packed red blood cells transfused were less in those
patients receiving HEA than those receiving HTIVA
(P=0.001, 0.04 and 0.015, respectively). Mean cen-
tral venous pressure was lower in HEA group than in
HTIVA group intraoperatively (P=0.019). Mean hemo-
globin concentrations and coagulation were similar be-
tween two groups. Neurological examinations of all pa-
tients were intact in the postoperative period. In a con-
tinuous study, HEA can increase blood flow in lower
extremity 25 and reduce blood loss and transfusion
requirement, so as to minimize venous stasis and venous
thrombosis, 26, 27 which has proven to be safe in patients
with hypertension, ischemic heart disease,28 chronic re-
nal insufficiency, and in the elderly.29
Mechanical prophylaxis-intermittent pneumatic
compression    The objective of mechanical prophy-
laxis is to substitute the action of the muscle pumps of
the legs that are normally activated during ambulation.
Intermittent pneumatic compression (IPC) involves
applying cuffs to the limbs that are automatically in-
flated and deflated by a pump. Some researches have
shown that the application of IPC immediately after
operation increases the velocity and volume of venous
flow, preventing or minimizing the formation and propa-
gation of clots.30 Thus, the authors apply IPC as soon
as the patient reaches the recovery room.31 Some au-
thors have advocated IPC during surgery.32 More
recently, some authors used portable pneumatic com-
pression device to prevent VTED. In the study, the au-
thors compared a miniaturized, portable, sequential,
pneumatic compression device — ActiveCare continu-
ous enhanced circulation therapy (CECT) system,
Aqiva, Israel, with a non-mobile, nonsequential device
on the ability to prevent postoperative DVT after joint
arthroplasty. All patients were treated with low-molecu-
lar-weight heparin, application of any of the two devices
perioperatively, and routine duplex screening. The result
showed that the CECT system had better compliance
(83% vs 49%), lower rates of DVT (1.3% vs 3.6%), re-
duction in clinically important PE (0 vs 0.66%), and
shorter time length of hospital stay (4.2 days vs 5.0
days). The authors considered that the portable CECT
system could be used with low-molecular-weight hep-
arin for DVT prevention in high-risk orthopedic patients.33
Anticoagulants:    (1) Aspirin  Aspirin prophylaxis
is safe, well-tolerated, easy to administer and with
prompt effect. It requires no monitoring, has analgesic
and antipyretic effects and reduces the risk of ectopic
ossification.34
Pulmonary Embolism Prevention Trial conclusively
established the beneficial role of aspirin in reducing the
risk of postoperative thromboembolism. In this study,
160 mg of aspirin was administered preoperatively and
continued for 35 days postoperatively in the patients
undergoing hip-fracture surgery, hip arthroplasty and
knee arthroplasty. Objectively proven and adjudicated
symptomatic venous thromboembolic events up to the
day of hospital discharge were collected. While the
study demonstrated a statistically significant reduction
in VTE in 13 356 patients with hip fracture, from 2.5%
to 1.6%, no statistically significant reduction was observed
in 2 648 patients undergoing hip or knee arthroplasty
with 1.1% experiencing symptomatic VTE in the aspirin
group compared with 1.4% in the placebo group. The
Antiplatelet Trialists’ Collaboration assessed the efficacy
of aspirin among other antiplatelet drugs in preventing DVT
in 8 400 general surgical and orthopaedic patients in-
cluded in 53 published studies.35 In this overall group,
DVT was reduced from 34.8% to 26% (P<0.01), and PE
was reduced from 2.7% to 1.0% (P<0.01).
In a study of 3 473 consecutive patients undergoing
TKA,36 95% were treated with a regional anesthesia,
and all but 71 patients received aspirin (325 mg twice a
day for 6 weeks) as VTED prophylaxis. Those patients
not receiving aspirin were deemed to be at increased
risk and received warfarin for venous thromboembolic
prophylaxis. At only 6-week follow-up, fatal PE approxi-
mated 0.1% and readmission for nonfatal PE or proxi-
mal DVT occurred in 0.5% of patients; 8 patients (0.5%)
required aspiration of the knee for a postoperative
hematoma.
(2) Low molecular weight heparin (LMWH)   The
efficacy of LMWH is well documented. Eikelboom37 con-
ducted a meta-analysis to examine post-discharge
prophylaxis with LMWH after total hip replacement and
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demonstrated a reduction in symptomatic VTE from
4.3% to 1.4% with LMWH. Colwell and coworkers38
demonstrated a significantly lower rate of symptomatic
VTE in THA patients with LMWH (enoxaparin 30 mg sc
twice a day, 0.3%) than adjusted dose of warfarin (1.1%).
There were more major bleeding in the LMWH group
(1.2%) than in the warfarin group (0.5%), although this
difference was not statistically significant (P=0.055).
In 2008, Sharrock et al39 reviewed publications over
the last nine years and performed a meta-analysis of
28 038 patients which showed that PE occurs despite
the use of anticoagulants, and LMWH is associated
with the highest all-cause mortality of all the prophy-
lactic agents. Neviaser et al40 examined the records of
135 patients who underwent total joint arthroplasty, ex-
perienced an in-hospital PE, and received treatment
with enoxaparin at therapeutic doses (1 mg/kg body
weight).The type and frequency of complications were
determined and classified as major or minor. Twenty-
seven percent of patients experienced minor complica-
tions and 10% experienced major complications. The
incidence of major bleeding was substantially higher
than rates reported for nonsurgical patients. The overall
complication rate of enoxaparin treatment is similar to
that reported for unfractionated heparin treatment in this
setting, but the complications are less severe.
(3) Warfarin    Over the past three decades, inter-
rupted only by a transient surge in the popularity of
fractionated heparins, warfarin has enjoyed increasing
favor and is unarguably the most commonly used single
agent in North America for prophylaxis of VTED follow-
ing total joint arthroplasty.
  In Lieberman et al’s study,41 between 1987 and
1993, 1 099 primary and revision THA were performed
in 940 patients and the authors used low-dose warfarin
for prophylaxis against thromboembolic disease. The
average duration of prophylaxis was 15 days (range, 1-
29 days). The result showed that 12 total hip arthro-
plasties were associated with a symptomatic PE; the over-
all prevalence of this complication therefore was 1.1%
(95% confidence interval, 0.4% to 1.9%). Four pulmo-
nary emboli were diagnosed before discharge and 8
after discharge. A fatal PE occurred (0.1%). Patients who
had a history of symptomatic VTED had a significantly
increased risk of symptomatic PE after THA (P=0.001).
A major bleeding episode occurred after 32 total hip ar-
throplasties (2.9%). Patients who had a prothrombin time
of more than 17 seconds had a significantly increased
risk of hematoma formation (P=0.003). The author
thought that prophylaxis with low-dose warfarin is safe
and effective for the prevention of PE after THA.
   In a series of studies,42-45 the authors used extend
warfarin to prevent VTED in 3 293 patients undergoing
total hip  (n=1 972) or knee (n=1 321) arthroplasty from
1984 to 2003. The results showed that the overall read-
mission rate for VTE was 1.6% (38/2 449 patients who
did not receive warfarin) and 0.2% (2/884 patients who
received extended warfarin, P=0.0015) and readmission
for PE 0 (0/844 patients who received warfarin) and 0.7%
(17/ 2449 patients who did not, P=0.01) after total hip
and knee arthroplasties. So the authors thought ex-
tended low-intensity (international normalized ratio, 2.0)
warfarin prophylaxis reduces readmission rates asso-
ciated with all thromboembolic events (P=0.0015) and
PE (P=0.01) after total hip and knee arthroplasty, with a
low rate (0.1%) of clinically meaningful bleeding events.
Pendleton et al46 studied a single-center prospective
cohort of consecutive (n=351) post–joint arthroplasty/
revision patients who were initiated on warfarin using a
new initiation nomogram and then discharged to home
with home health services. The mean time to an inter-
national normalized ratio of 2.0 or higher was 5 days.
The result showed that adverse events were uncommon:
4 patients (1.14%) had VTE, 1 (0.28%) had major bleed-
ing episode, and 6 (1.7%) had minor bleeding. So the
authors thought that specific warfarin dosing nomogram
managed by an anticoagulation service and used in joint
arthroplasty/revision patients who are discharged to
home with home health services is effective anticoagu-
lation with few associated adverse events.
(4) Direct factor Xa inhibitors    Currently, there
are two drugs within this class in clinical development.
The first drug, apixiban, is a small-molecule, oral,
direct factor Xa inhibitor that selectively and reversibly
inhibits both free factor Xa and prothrombinase activity.
Apixaban has high oral bioavailability in large animals,
and a half-life of approximately 12 hours in humans.47 It
has been tested in subjects undergoing TKA in a large
phase II randomized trial with promising results.48
The second drug is rivaroxaban, which is a small-
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molecule, oral, direct factor Xa inhibitor that selectively
and reversibly inhibits free and clot-associated factor
Xa activity, as well as prothrombinase activ ity.
Rivaroxaban has recently been approved for the pre-
vention of VTE after total hip or knee replacement in
European Union and several other countries, based on
the results of the phase III record program, which com-
prised four large studies in more than 12 500 patients
in total. The results of this study demonstrated that
extended prophylaxis with rivaroxaban 10 mg/d was
superior to short-term prophylaxis with enoxaparin 40
mg /d for the prevention of VTE, including symptomatic
events, after THA. Despite rivaroxaban being given for 3
weeks longer than enoxaparin, the incidence of major
bleeding at 5 weeks was 0.1% in both groups. This
study confirmed the benefits of extended prophylaxis
over short-term prophylaxis and the safety of its use.49
(5) Direct thrombin inhibitors (DTIs)    DTIs are
small molecules that inhibit thrombin directly, which
allows them to inhibit both free and clot-bound thrombin.
It constitutes a potential advantage over the indirect
thrombin inhibitors.50
The first agent to be developed in this class was
ximelagatran, a prodrug of the active form melagatran.
Its mechanism of action involves a direct inhibition of
the active site of thrombin in either its circulation or
clot-bound forms, thus preventing the extension of a
previously formed clot. Initial studies showed that this
drug was efficacious and safe for VTE prophylaxis after
orthopedic surgery; however, a meta-analysis showed
that although in patients with THR the use of ximelagatran
resulted in less VTE events compared with LMWH, it
was associated with a 3.33-fold increase in major
bleeding.51
Dabigatran etexilate is a prodrug of dabigatran, a spe-
cific and reversible thrombin inhibitor. Three phase III stud-
ies investigated oral dabigatran etexilate for the preven-
tion of VTE after major orthopaedic surgery. These stud-
ies compared oral dabigatran etexilate 150-220 mg once
daily with the subcutaneous LMWH. The result showed
that dabigatran was either non-inferior or inferior to the
LMWH enoxaparin with a similar safety profile.52
Multimodal thromboprophylaxis    As mentioned
above, the aetiology of VTE is multifactorial, including
the well-known Virchow’s triad of hypercoagulability,
venous stasis and endothelial damage. It is therefore
appropriate to use a multimodal approach to
thromboprophylaxis. The researcher continues for the
ideal combination of agents and factors, including
chemical, mechanical, surgical or anesthetic, which
offers efficient thromboprophylaxis and is associated
with the lowest incidence of adverse effects.
Sarmiento et al53 investigated the effectiveness of
aspirin, a program of intraoperative and postoperative
exercises, and graded elastic stockings or intermittent
compression devices as prophylaxis against throm-
boembolic disease in a series of 1 267 patients who
had 1 492 total hip arthroplasties. Regional (epidural)
anesthesia was used for 1 099 arthroplasties (73.7%),
and general anesthesia was used for 393 procedures
(26.3%). The result showed that a fatal PE occurred
after two arthroplasties (0.13%), a nonfatal PE was di-
agnosed in 14 patients (0.94%), and DVT developed in
15 patients (1.01%). Compared with general anesthesia,
the use of regional anesthesia was associated with a
significantly lower rate of nonfatal PE (P<0.001) and DVT
(P<0.025). So the authors thought the multimodal pro-
phylaxis was effective and safe for venous thrombolism
after THA.
Dorr et al54 retrospectively reviewed the records on
1 179 consecutive total joint arthroplasties in 970 pa-
tients who underwent primary and revision total hip and
knee replacement. Preoperatively, the patients were
divided into two groups according to risk stratification.
Eight hundred and fifty-six patients (1 046 operations)
were considered to be at low risk and were managed
with aspirin, dipyridamole or clopidogrel bisulfate as well
as intermittent pneumatic calf compression devices.
One hundred and fourteen patients (133 operations) were
considered to be at high risk and were managed with
low molecular weight heparin or warfarin and intermit-
tent pneumatic calf compression devices. The results
showed that there were 3 symptomatic pulmonary em-
boli (0.25%), and 5 clinically symptomatic deep venous
thrombi (0.4%) and no fatal pulmonary emboli in both
groups. Sixty-one asymptomatic deep venous thrombi
(5.2%) were found with use of routine postoperative
Doppler ultrasound scans.
A series of clinical, basic and applied researches
on thromboembolic disease after total joint arthroplasty
were conducted in hospital for special surgery during
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three decades.12,22-24,27,31,37,55-61 A multimodal prophylaxis
protocol was developed for special surgery and fully
implemented since 1995, consisting of stratifying the
individual patient’s risk and implementing a series of
safe preventive measures before, during, and after sur-
gery to reduce the risk of VTE and bleeding.
The measures include discontinuation of procoagulant
medication and intraoperative intravenous heparin after
acetabular work during THA, the use of pneumatic com-
pression devices, elastic stockings, and frequent and
vigorous dorsiflexion of the ankles and prompt mobili-
zation of patients after surgery to diminish venous stasis.
If these safe measures are observed, postoperative phar-
macologic prophylaxis does not need to be aggressive
in the patients without predisposing factors for VTE and
since the mid 1970s, enteric-coated aspirin has been
the authors’ preferred postoperative chemoprophylaxis.
The authors indicate warfarin for patients who have rec-
ognized predisposing factors for VTE or who were al-
ready prescribed warfarin for preexisting comorbidities.
Salvati et al 62 have conducted retrospectively three
decades of thromboprophylaxis research for total THA.
According to the author’s clinical experience, more than
5 000 total hip arthroplasties were performed during the
last decade and closely followed up prospectively for a
minimum of 3 months. The result clearly shows that
with multimodal prophylaxis, the prevalence of throm-
boembolism is very low (the incidence of clinical DVT
being 2.5%; symptomatic PE 0.6%). In a recent paper,
also 10 000 total hip and knee replacements in Hospi-
tal for Special Surgery in New York, USA, demonstrates
that the multimodal prophylaxis is safe and effective,
resulting in a very low prevalence of thromboembolism,
bleeding and all-cause mortality.15
Conclusion
VTED continues to be a serious complication of total
hip and knee arthroplasty. The pathogenesis of VTE is
multifactorial and includes the well-known Virchow’s
triad of hypercoagulability, venous stasis and endothe-
lial damage. Therefore, it is appropriate to use a
multimodal approach to thromboprophylaxis.
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